logo-loader
viewCytoDyn Inc.

CytoDyn to submit trial designs of remdesivir vs leronlimab and in combination to battle coronavirus

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan and Chief Science Officer Dr Jacob Lalezari tells Proactive the biotech is set to submit a clinical trial design to the FDA to compare the effectiveness of leronlimab versus Gildead's remdesivir, and in combination with remdesivir for the treatment of coronavirus.

Pourhassan says he would expect to submit the trial design to the FDA by the end of the week.

Quick facts: CytoDyn Inc.

Price: 4.79 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $2.49 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn to submit request for pre-submission meetings in U.K. for Leronlimab

CytoDyn Inc (OTCQB: CYDY) CEO Nader Pourhassan shared news with Steve Darling from Proactive that the company has started the process of requesting meetings in the U.K. for leronlimab as an HIV treatment as well as for emergency approval of leronlimab for COVID-19 patients with mild-to-moderate...

1 day, 17 hours ago

2 min read